[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201101568A1 - Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta - Google Patents

Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta

Info

Publication number
EA201101568A1
EA201101568A1 EA201101568A EA201101568A EA201101568A1 EA 201101568 A1 EA201101568 A1 EA 201101568A1 EA 201101568 A EA201101568 A EA 201101568A EA 201101568 A EA201101568 A EA 201101568A EA 201101568 A1 EA201101568 A1 EA 201101568A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pkc
teta
inhibitors
treatment
treating
Prior art date
Application number
EA201101568A
Other languages
English (en)
Inventor
Мэрианне Браун
Майкл Дастин
Александра Занин-Жоров
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Нью-Йорк Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх, Нью-Йорк Юниверсити filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201101568A1 publication Critical patent/EA201101568A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В заявке описан способ лечения различных заболеваний и нарушений, которые опосредуются или поддерживаются активностью PKC-тета, включая иммунологические нарушения и атеросклероз. Конкретно, в заявке описан способ лечения иммунологического нарушения или атеросклероза у пациента, заключающийся в том, что обрабатывают ex vivo кровь, взятую у пациента, или определенный компонент этой крови ингибитором PKC-тета и затем снова вводят обработанную кровь пациенту.
EA201101568A 2009-04-28 2010-04-28 Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta EA201101568A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17323709P 2009-04-28 2009-04-28
PCT/US2010/032707 WO2010126967A1 (en) 2009-04-28 2010-04-28 Ex-vivo treatment of immunological disorders with pkc-theta inhibitors

Publications (1)

Publication Number Publication Date
EA201101568A1 true EA201101568A1 (ru) 2012-05-30

Family

ID=42332785

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101568A EA201101568A1 (ru) 2009-04-28 2010-04-28 Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta

Country Status (14)

Country Link
US (1) US20120196919A1 (ru)
EP (1) EP2445503A1 (ru)
JP (1) JP2012525403A (ru)
KR (1) KR20120005460A (ru)
CN (1) CN102421435A (ru)
AU (1) AU2010241701A1 (ru)
BR (1) BRPI1014775A2 (ru)
CA (1) CA2760305A1 (ru)
CL (1) CL2011002690A1 (ru)
EA (1) EA201101568A1 (ru)
IL (1) IL215939A0 (ru)
MX (1) MX2011011290A (ru)
NZ (1) NZ595331A (ru)
WO (1) WO2010126967A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3789056T3 (da) 2007-08-31 2025-06-23 Seastar Medical Inc Indretninger til selektiv cytoferese
WO2010135255A1 (en) 2009-05-18 2010-11-25 Therakos, Inc. Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
EP2627369B1 (en) 2010-10-15 2022-01-12 SeaStar Medical, Inc. Cytopheresic cartridge and use thereof
US20140186372A1 (en) * 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
AR087346A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Formulaciones de compuestos de tiofeno
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
CA2860831A1 (en) 2012-01-09 2013-07-18 H. David Humes Cartridge and method for increasing myocardial function
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
JP6560200B2 (ja) 2013-10-17 2019-08-14 ザ ジェネラル ホスピタル コーポレイション 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
EP3221308B1 (en) 2014-11-21 2018-09-19 F2G Limited Antifungal agents
US10906982B2 (en) 2015-05-15 2021-02-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
US10993959B2 (en) 2015-09-04 2021-05-04 Regents Of The University Of Minnesota Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2004043386A2 (en) * 2002-11-08 2004-05-27 Tolerrx, Inc. Molecules preferentially associated with effector t cells and methods of their use
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
US7601714B2 (en) * 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta

Also Published As

Publication number Publication date
EP2445503A1 (en) 2012-05-02
AU2010241701A1 (en) 2011-10-13
CA2760305A1 (en) 2010-11-04
JP2012525403A (ja) 2012-10-22
CN102421435A (zh) 2012-04-18
CL2011002690A1 (es) 2012-04-27
MX2011011290A (es) 2012-02-13
BRPI1014775A2 (pt) 2016-04-19
WO2010126967A1 (en) 2010-11-04
IL215939A0 (en) 2012-01-31
NZ595331A (en) 2013-08-30
KR20120005460A (ko) 2012-01-16
US20120196919A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA201500362A1 (ru) Ингибиторы rho-киназы
WO2010091049A3 (en) Diagnosis and treatment of cancer
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EA201101111A1 (ru) Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EP2350012A4 (en) QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN AMINOPEPTIDASE METHIONINE AND SIRT1, AND METHODS OF TREATING DISORDERS
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης